Drug Trial Radar · NCT07233655
A Phase II Trial of SHR-3045 Injection in Patients With Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
30
Actual
Start
Jan 19, 2026
Primary completion
Apr 21, 2026
Study completion Jul 2026
Sponsor
- Lead sponsor
- Guangdong Hengrui Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is ongoing to explore the efficacy and safety of different strengths of SHR-3045 injection in moderate to severe active rheumatoid arthritis.
Conditions
- Moderate to Severe Active Rheumatoid Arthritis
Interventions
SHR-3045 InjectionDrug
SHR-3045 injection.
SHR-3045 Injection PlaceboDrug
SHR-3045 injection placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The percentage of subjects who achieved a 20% improvement in the American College of Rheumatology Rheumatoid Arthritis (RA) disease activity assessment core set.Time frame: After 14 weeks of treatment.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People 's Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.